Skip to Main Content

Nina Kadan-Lottick, MD, MSPH

Associate Professor of Pediatrics (Hematology / Oncology); Medical Director, HEROS Program

Research Summary

I am a pediatric hematologist-oncologist and epidemiologist focused on improving outcomes in patients previously treated for childhood cancer.

Extensive Research Description

Dr. Kadan-Lottick's research seeks to reduce late complications and improve quality of life in pediatric and adult survivors of childhood cancer. She established the Yale HEROS Survivors’ Program in 2003 as one of the first of its kind in the United States. Prior to Yale, she completed a post-doctoral fellowship in cancer survivorship with Dr. Leslie Robison working on the NCI-funded ongoing Childhood Cancer Survivorship Cohort (CCSS). Dr. Kadan-Lottick is the current and past PI of multiple survivorship studies funded by the National Cancer Institute, the American Cancer Society, St. Baldrick’s Foundation, and the Hyundai Foundation. She is the chair of five current/past multi-site Children’s Oncology Group (COG) studies that measure physical, neuro-cognitive, psychological, and neurological outcomes in children with cancer. She has experience successfully coordinating different sites, achieving enrollment goals, and overcoming methodological issues. She is a member of the COG Survivorship Steering Committee, COG Acute Lymphoblastic Leukemia Committee, and serve as the Yale site PI for COG Consortium studies. Dr. Kadan-Lottick has built productive collaborations with co-investigators at Yale and around the world.

Coauthors

Research Interests

Health Services; Medical Oncology; Pediatrics; Quality of Life; Cancer Survivors

Selected Publications

Clinical Trials

ConditionsStudy Title
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
PediatricsPrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Bones and JointsEffects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Supportive Care; Pediatrics; PreventionStepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Leukemia, not otherwise specified; Leukemia, other; PediatricsA Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase
Leukemia, otherA Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement
Brain and Nervous System; PediatricsA Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Brain and Nervous System; PediatricsA Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Leukemia, not otherwise specified; Leukemia, other; PediatricsAn Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-derived Asparaginases
Leukemia, not otherwise specified; Leukemia, other; PediatricsA Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Hodgkin's LymphomaA Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Hodgkin's LymphomaAn Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
Leukemia, not otherwise specified; Leukemia, otherA Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
Leukemia, other; PediatricsA Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
LiverPediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Lymphoid LeukemiaA Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Leukemia, not otherwise specified; Leukemia, otherA Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Other Hematopoietic; Pediatrics; Sickle Cell DisordersA Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
Bones and Joints; Brain and Nervous System; Leukemia, not otherwise specified; Leukemia, other; Lymphoid LeukemiaNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol